New discoveries about how the immune system fights coronavirus

The immune system, on detecting the novel coronavirus (SARS-CoV-2) or another invading virus, sends a mass of antibodies to bind to it, thereby blocking the virus’s ability to attach to cells and marking it for destruction by other cells. Recent new research shows how this process works in people who have successfully recovered from Covid-19 disease and contains information that may also help other patients.
Until now, scientists have focused on the “spike” (thorn) portion—the receptor-binding domain—which the virus uses to access and attach to human cells.

Figure 1 caption: SARS-CoV-2 is an RNA virus covered by a lipid envelope. This virus attaches to our cells using its protein called spike (thorn).
This part of the coronavirus binds directly to a person’s cells to infect them and is the region that researchers prioritize most for vaccine and drug development. Last year, the US Food and Drug Administration (FDA) authorized monoclonal antibody treatments for emergency use; these treatments also targeted the same region.
Noticing the difference...
A team led by immunologists Gregory Ippolito and Jason Lavinder at the University of Texas at Austin examined blood samples from four people who had recovered from Covid-19 more closely and discovered that most of the antibodies their bodies produced to fight the coronavirus actually targeted the other side of the spike portion. In fact, as many as 80% of the antibodies target other spike protein regions.
Ippolito explains: "These antibodies target another area of the canopy of the umbrella-shaped protein. It is this part of the spike protein, called the N-terminal domain, that mutates most frequently (the antibody-binding site shown in blue below). Changes in this region are also responsible for many variants of concern. Such variants can avoid detection by some of the most common defensive antibodies and thereby evade the immune system."

Figure 2 caption: Analysis of blood plasma samples from people who recovered from SARS-CoV-2 infections shows that most circulating antibodies—approximately 84% on average—target areas outside the receptor-binding domain of the viral spike protein (RBD, green), the N-terminal domain (NTD, blue) and the S2 subunit (red, yellow). Illustration source: University of Texas, Austin.
The new discovery may provide more effective protection against Covid-19
But another large group of antibodies targets the stalk of the spike, called the S2 subunit. This is reassuring because scientists reported that this region does not frequently undergo mutation. Therefore, if antibodies that recognize the virus can neutralize it (bind before it enters a cell), they should, against any variant, offer a layer of protection.
No S2-binding antibody has yet been found to be strongly protective, but Lavinder says that if some can be found, they could play a role in next-generation vaccines developed to deal with variants. This could even extend to a vaccine protecting against all coronaviruses, not just Covid-19.
Ippolito summarizes these new discoveries as follows: “The main idea here is that this region could be a good pan-coronavirus vaccine because it is significantly conserved in all coronaviruses. It is important for the strategic design of vaccines in the future.”
RELATED TOPICS
- Covid-19 current world and Turkey statistics
- Breaking news and scientific developments about coronavirus
Sources
2. Voss W.N. et al. (May 4, 2021). Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science: https://science.sciencemag.org/
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.